Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Gastric Cancer

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 7 articles:
HTML format



Single Articles


    June 2025
  1. QI C, Liu C, Peng Z, Zhang Y, et al
    Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
    Lancet. 2025;405:2049-2060.
    PubMed     Abstract available


    May 2025
  2. SUNDAR R, Nakayama I, Markar SR, Shitara K, et al
    Gastric cancer.
    Lancet. 2025 May 1:S0140-6736(25)00052-2. doi: 10.1016/S0140-6736(25)00052.
    PubMed     Abstract available


    June 2024
  3. SINGH S, Halperin D, Myrehaug S, Herrmann K, et al
    [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high?dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomise
    Lancet. 2024;403:2807-2817.
    PubMed     Abstract available


  4. LIOU JM, Malfertheiner P, Smith SI, El-Omar EM, et al
    40 years after the discovery of Helicobacter pylori: towards elimination of H pylori for gastric cancer prevention.
    Lancet. 2024;403:2570-2572.
    PubMed    


    December 2023
  5. SMYTH EC, Sundar R
    Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer.
    Lancet. 2023;402:2168-2170.
    PubMed    


    May 2023
  6. SHITARA K, Lordick F, Bang YJ, Enzinger P, et al
    Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 tr
    Lancet. 2023;401:1655-1668.
    PubMed     Abstract available


    March 2023
  7. O'MAHONY D, Power SP, Power DG
    Human epidermal growth factor receptor 2-positive metastatic gastric cancer in complete sustained remission with trastuzumab.
    Lancet. 2023;401:772.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Gastric Cancer is free of charge.